Invokana Dosing & Indications

Kidney, heart and blood drop icon image
 

Invokana Dosing & Indications

Indication

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:​1

  • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • in addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effect on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1 of the SmPC.1

Dosing

It’s simple to prescribe Invokana for your patients with diabetic kidney disease (DKD).

For the treatment of DKD in adults with T2DM as add-on to standard of care, a dose of 100 mg once-daily should be used.1
See SmPC Section 4.2 for dosing details

A kidney symbol showing drug dosage quantity
A kidney symbol showing drug dosage quantity
 
What to do if tighter glycaemic control
is needed?
eGFR ≥60 Use Invokana 300 mg rather than 100 mg
eGFR <60 Consider adding another anti-hyperglycaemic agent
Abbreviations

DKD: Diabetic Kidney Disease; eGFR: estimated Glomerular Filtration Rate; SmPC: Summary of Product Characteristics; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/ Creatinine Ratio.

References
  • 1. Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: https://www.medicines.org.uk/emc/product/8855/smpc and https://www.medicines.org.uk/emc/product/12057/smpc [Accessed May 2021].
Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.